Medicilon-MPI Preclinical Research (Shanghai) LLC to Complete Pre-Clinical Work on South Korean Anti-Depressant
October 20, 2011 -- Medicilon, a Shanghai CRO, has agreed to complete the pre-clinical development of a new anti-depressant developed by SK Biopharmaceuticals of South Korea. Medicilon will prepare the work for both China and US approval of the small molecule, known as SKL-PSY, which is being developed as a treatment of depression and bipolar disorder. More details....